Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price shot up 4.4% on Thursday . The stock traded as high as $1.92 and last traded at $1.92. 9,470 shares traded hands during mid-day trading, a decline of 69% from the average session volume of 30,220 shares. The stock had previously closed at $1.84.
Humacyte Price Performance
The company has a fifty day simple moving average of $1.86 and a two-hundred day simple moving average of $1.83.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- How Can Investors Benefit From After-Hours Trading
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Why Invest in High-Yield Dividend Stocks?
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Low PE Growth Stocks: Unlocking Investment Opportunities
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
